The world of dividend investing is one I think is worth exploring. Even for the most growth-conscious investors out there, ...

William Blair analysts cut AbbVie’s FY2025 earnings estimate to $11.82 per share from $12.21, citing revised outlooks. Other ...

AbbVie employees in Asia participated in the tenth Week of Possibilities (WOP), the AbbVie Foundation's annual global ...

A federal court in Missouri has dismissed a legal challenge by drugmaker AbbVie to the state’s new 340B contract pharmacy law, which aims to regulate how pharmaceutical companies interact with ...

This was the stock's third consecutive day of losses.

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...

AbbVie has updated its 2025 earnings guidance after taking an $823 million acquired in-process R&D (IPR&D) expense in Q2.

AbbVie Inc. (NYSE:ABBV) is one of the 7 most undervalued pot stocks to buy according to analysts. On July 3, the company ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...